Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

SAN DIEGO–(BUSINESS WIRE)– #breastcancer–Biocept receives Medicare coverage for breast cancer assay to detect and analyze HER2 biomarker and announces CNSide and COVID-19 testing updates.
Click here to view original post